Redeye believes that Alzinova offers a rare investment opportunity in the Scandinavian equity markets
Date: 2022-07-12Redeye discussed the outlook forward and recent rights issue, among other things. "We believe that Alzinova offers a rare investment opportunity in the Scandinavian equity markets as its main candidate, ALZ-101, is one of the very few disease-modifying therapies for Alzheimer’s disease in clinical development."
“The candidate’s vaccine approach is unique and should suit well for a life-long indication, such as Alzheimer’s, potentially offering a more cost-efficient alternative than its peers. With the company now having saturated its capital need and secured a financial runway until 2024, we believe that Alzinova has set a starting point for long-term value creation. Accordingly, we forecast ALZ-101’s potential annual peak sales at more than USD 5 billion, in 2036.”